Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE: This study was conducted to evaluate the relationship of p53 and Ki67 expression with prognostic factors in patients who underwent surgery due to a diagnosis of endometrial cancer, and to evaluate their use as molecular markers that can help with survival prediction.
📊
Key Findings & Data:STUDY DESIGN: This retrospective cohort study included patients who underwent surgery for endometrial cancer indication at the Gynecologic Oncology Clinic of the University of Health Sciences Tepecik Training and Research Hospital between 2011 and 2019, and whose p53 and Ki67 from the dissected material were pathologically studied and who underwent pelvic/paraaortic lymph dissection between the relevant dates.
💡
Conclusion & Impact:Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE: This study was conducted to evaluate the relationship of p53 and Ki67 expression with prognostic factors in patients who underwent surgery due to a diagnosis of endometrial cancer, and to evaluate their use as molecular markers that can help with survival prediction. STUDY DESIGN: This retrospective cohort study included patients who underwent surgery for endometrial cancer indication at the Gynecologic Oncology Clinic of the University of Health Sciences Tepecik Training and Research Hospital between 2011 and 2019, and whose p53 and Ki67 from the dissected material were pathologically studied and who underwent pelvic/paraaortic lymph dissection between the relevant dates. RESULTS: The study included 140 patients who met the inclusion criteria, 60% (n=84) of whom had endometrioid type endometrial carcinoma and 40% (n=56) had non-endometrioid type endometrial carcinoma. Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p
🔖
Cite This Article
KARADENIZ, T., SANCI, M., BAYRAKTAR, B., SAHIN, Z. (2022). The Impact of p53 and Ki67 Expression in Endometrial Cancer and its Effect on Survival. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 28 - Sayı: 1, 82–88. https://ajindex.com/articles/525809
Colombo N, Creutzberg C, Amant F, Bosse T, GonzálezMartín A, Ledermann J, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41. Doi: 10.1093/annonc/ mdv484. Erratum in: Ann Oncol. 2017;28(suppl 4): iv167-iv168
Carlson JW, Kauderer J, Hutson A, Carter J, Armer J, Lockwood S, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol. 2020;156(2): 467-74. Doi: 10.1016/j.ygyno.2019.10.009
Ghezzi F, Uccella S, Cromi A, Bogani G, Robba C, Serati M, Bolis P. Lymphoceles, lymphorrhea, and lymphedema after laparoscopic and open endometrial cancer staging. Ann Surg Oncol. 2012;19(1):259-67. Doi: 10.1245/ s10434-011-1854-5
Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;10(10): CD007585. Doi: 10.1002/14651858.CD007585.pub4
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16. Doi: 10.1093/jnci/djn 397
Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;10(10): CD007585. Doi: 10.1002/14651858.CD007585.pub4
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403-12. Doi: 10.1182/blood-2012-09-458265
Kreipe H, Ki67-Tumorheterogenität vs. Assayhetero - genität [Ki67: biological intertumor variance versus variance of assay]. Pathologe. 2018;39(Suppl 2):272-77. Doi: 10.1007/s00292-018-0502-2
Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105(2):109. Doi: 10.1016/j.ijgo.2009.02.010
Kurman RJ, Carcangiu ML, Herrington S, Young RH. Tumours of the Female Reproductive Organs. WHO classification of tumours. Lyon: IARC Press; 2014
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. Doi: 10.1016/ 0090-8258(83)90111-7
Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of